Are Peptides Legal Now? The 2026 HHS Peptide Policy Explained
What changed under the October 2026 HHS peptide policy, what did not change, and the ten conditions licensed 503A pharmacies must follow.
By Gulf Breeze Apothecary
Published November 4, 2026
The short answer
Partly. On October 28, 2026, HHS said it will not take enforcement action against state-licensed pharmacies that compound six peptides (BPC-157, TB-500, Epitalon, MOTS-c, KPV and Semax) for an individual patient with a prescription, as long as ten conditions are met. None of the six is FDA-approved. Blends are excluded. HHS can withdraw the policy at any time.
What changed on October 28, 2026
HHS gave licensed pharmacies a temporary, conditional path to compound six peptides that were previously off-limits. The notice (opens in a new tab) was filed October 28 and published in the Federal Register on October 30 under docket HHS-OASH-2026-0496. It was issued by the HHS Secretary's office, not by FDA.
The key sentence: HHS "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician" compounding with one of the six listed peptides. That holds until FDA finishes a final rule on each peptide.
Why this mattered. Federal law lets a 503A pharmacy compound from a bulk ingredient only if it has a USP monograph, is part of an FDA-approved drug, or appears on FDA's 503A bulks list. None of the six met any of those tests. From September 2023 they also sat on FDA's Category 2 list of substances that raise significant safety concerns.
HHS's stated reason. The policy aims to pull patients away from "research-use-only" peptides made by foreign suppliers. HHS says a tested, prescription-only pharmacy product is the safer alternative. It also cites new lot-level testing data and documented human use that FDA's reviewers did not have in 2023.
What did not change
The policy is a decision not to enforce, not an approval, and it can end without notice.
- Not FDA approval. The notice states that compounded drugs are not FDA-approved and that FDA does not review their safety, effectiveness or quality. Neither document finds any of the six safe or effective.
- Not binding. The policy "does not establish any rights for any person and is not binding on HHS or the public."
- Not permanent. HHS may revisit it, in whole or in part, if a safety signal or product quality problem appears. FDA rulemaking on the 503A bulks list is expected to take 12 to 24 months, and the final rule could add or exclude any of the six.
- Not for other peptides. Any peptide not on the list of six is exactly where it was on October 27.
- Not for outsourcing facilities. The policy covers 503A compounding for named patients. It does not extend to 503B outsourcing facilities that make office stock for clinics.
- Not for research-use-only sellers. Online "research chemical" sales, imports and personal possession are not addressed at all.
- Not a state override. State pharmacy laws and boards still apply.
- Not for athletes. BPC-157 remains on the World Anti-Doping Agency's prohibited list, and USADA (opens in a new tab) still warns athletes against it.
The six peptides and how each can be compounded
Each peptide is covered only in one chemical form and only for specific routes. Anything outside these limits is outside the policy.
| Peptide | Covered form | Permitted routes | Not covered |
|---|---|---|---|
| BPC-157 | Acetate | Subcutaneous, intramuscular, oral, topical | Nasal; blends |
| TB-500 | Acetate | Subcutaneous, intramuscular | Oral, topical, nasal; blends |
| Epitalon | Acetate | Subcutaneous, intramuscular, in intermittent courses | Continuous dosing; other routes |
| MOTS-c | Acetate | Subcutaneous, intramuscular | Oral, topical, nasal |
| KPV | Acetate | Topical, oral | Injections |
| Semax | Free base | Intranasal | Injections; other routes |
Source: HHS policy, Appendix B (opens in a new tab).
Two route rules catch people out. Oral BPC-157 or KPV requires documentation that the specific formulation reaches adequate levels in humans. And the only delivery device that may come with any of these products is an FDA-cleared syringe, so pens and auto-injectors are out.
The ten conditions, in plain English
A pharmacy is inside the policy only if all ten conditions are met. Most of the burden falls on where the raw peptide comes from and how it is tested.
| # | What the policy requires | What it means for you |
|---|---|---|
| 1 | The peptide is one of the six listed in Appendix A | No other peptide is covered |
| 2 | The peptide matches the exact identity and routes in Appendix B | Wrong salt form or wrong route means not covered |
| 3 | The raw peptide comes from an FDA-registered facility with a certificate of analysis meeting FDA's testing criteria | Identity, purity, potency, endotoxin, heavy metals and microbes are all tested |
| 4 | The original manufacturer, not just a distributor, is FDA-registered and follows CGMP, with its address on the certificate | A relabeled "research" powder does not qualify |
| 5 | The pharmacy reports products, serious adverse events and quality problems to FDA's MedWatch program and to the states involved | Side effects you report become part of a federal safety record |
| 6 | The label reads: "This is a compounded drug product. Not for resale." | Look for this exact statement |
| 7 | Each product contains a single active ingredient: one listed peptide and nothing else active | No blends: not BPC-157 with TB-500, and not a peptide with semaglutide or any other active |
| 8 | Oral forms have documented human bioavailability for that specific formulation | Oral options may be limited |
| 9 | The only device included is an FDA-cleared syringe | No pens or auto-injectors |
| 10 | All other federal compounding law applies, including sanitary conditions and a patient-specific prescription | You need your own prescription from a licensed prescriber |
Source: HHS policy, conditions 1–10 (opens in a new tab). The testing standard behind condition 3 lists more than 15 test categories, far beyond the two (purity and mass) on a typical research-peptide certificate.
How we got here: 2023 to today
The six peptides went from restricted to conditionally available in about three years, and the final rule is still ahead.
| Date | What happened |
|---|---|
| Sep 29, 2023 | FDA places all six (and others) in Category 2, citing immunogenicity, impurity concerns and limited human safety data |
| Feb 27, 2026 | HHS Secretary Kennedy says about 14 of the 19 restricted peptides could be reclassified (Pharmacy Times (opens in a new tab)) |
| Apr 2026 | FDA removes 12 peptides, including all six, from Category 2 after the nominations are withdrawn, and schedules advisory review (FDA (opens in a new tab)) |
| Jul 23–24, 2026 | FDA's Pharmacy Compounding Advisory Committee narrowly recommends all six. BPC-157, KPV and TB-500 pass 8–6; MOTS-c passes 7–5. FDA staff had recommended against every one (AJMC (opens in a new tab)) |
| Oct 28, 2026 | HHS files the enforcement discretion policy |
| Oct 30, 2026 | Policy published in the Federal Register; two-week comment period opens |
| Mid-Nov 2026 | Public comments close (two weeks after publication) |
| Feb 2027 | Advisory committee scheduled to review five more peptides (AJMC (opens in a new tab)) |
| 2027–2028 | FDA rulemaking on the 503A bulks list, estimated at 12 to 24 months (Frier Levitt (opens in a new tab)) |
The policy is also contested. The Partnership for Safe Medicines has petitioned FDA to disregard the advisory vote, arguing the evidence is thin and the panel was improperly formed.
Does your state allow it?
The federal policy is a floor, not a guarantee: your state's pharmacy rules still decide what a pharmacy may dispense to you. The policy does not displace state board requirements, and at least one industry leader has warned that states may not follow the federal government in relaxing their rules.
Gulf Breeze Apothecary is a Florida-licensed 503A compounding pharmacy regulated by the Florida Board of Pharmacy. We are LegitScript-certified and licensed to serve patients in 36 states. If you live outside those states, we cannot fill your prescription. Your prescriber can direct it to a licensed pharmacy where you live.
How to get a peptide prescription filled the legal way
The only route the policy covers is a prescription for you, from a licensed prescriber, filled by a licensed pharmacy.
- Talk to a licensed prescriber. Discuss whether a peptide makes sense for you, what the evidence does and does not show, and the risks.
- Get a patient-specific prescription. It must name you, a single peptide and a covered route (for example, intranasal Semax, not injectable Semax).
- Send it to a licensed 503A pharmacy. The pharmacy confirms the form and route are covered and that its raw material meets the sourcing and testing conditions.
- Check the label. It should read "This is a compounded drug product. Not for resale." and explain how to report side effects.
- Report problems. Tell your prescriber and pharmacy about side effects or quality concerns. You can also report directly to FDA MedWatch (opens in a new tab).
For general pharmacy and provider information, visit For Providers. Availability and suitability are confirmed individually by the pharmacy and prescriber.
Frequently asked questions
Is BPC-157 legal now? A licensed 503A pharmacy may compound BPC-157 for a patient with a prescription without federal enforcement, if all ten conditions are met. It is still not FDA-approved, and the policy is temporary and non-binding.
Are these peptides FDA-approved? No. None of the six is FDA-approved, and the policy makes no finding that any of them is safe or effective.
Can I get the BPC-157 and TB-500 "Wolverine stack" from a pharmacy? Not as one product. Condition 7 limits each compounded product to a single active ingredient, so any blend is outside the policy, including a peptide combined with a non-peptide active.
Can I order these online without a prescription? No. The policy covers only compounding for a named patient with a valid prescription. "Research use only" websites are not covered.
Is injectable Semax covered? No. Semax is covered for intranasal use only. KPV is covered only as topical or oral.
Is oral BPC-157 covered? Oral is a permitted route, but the pharmacy must document that its specific oral formulation reaches adequate levels in humans.
Can my clinic or med spa keep these as office stock? The policy covers patient-specific 503A compounding. It does not extend to 503B outsourcing facilities, which supply clinics with office stock.
How long will this last? Until FDA finishes a final rule on each peptide, which is estimated to take 12 to 24 months. HHS can also end it sooner if safety or quality problems appear.
Can competitive athletes use these? The HHS policy changes nothing in sport. BPC-157 is prohibited by the World Anti-Doping Agency, and athletes should check every peptide with their governing body.
Can I comment on the policy? Yes, at regulations.gov under docket HHS-OASH-2026-0496, until two weeks after the October 30, 2026 publication date.
Sources
- HHS Enforcement Discretion Policy, conditions and Appendices A–B (opens in a new tab)
- Federal Register notice, FR Doc. 2026-22192 (opens in a new tab)
- ABC News: Some wellness peptides will become widely available, HHS says (opens in a new tab)
- AJMC: 5 things to know about HHS's interim peptide compounding policy (opens in a new tab)
- AJMC: FDA panel backs 6 peptides for compounding (opens in a new tab)
- Frier Levitt: HHS peptide compounding enforcement discretion policy (opens in a new tab)
- FDA: Interim 503A bulks list categories (opens in a new tab)
This article explains a federal policy for general education. It is not medical or legal advice and does not recommend any treatment. Compounded medications are not FDA-approved and require a prescription. Talk with your prescriber about whether any medication is right for you.